MoonLake Immunotherapeutics

NASDAQ:MLTX

Biotechnology

Healthcare
$10.79 +0.69%

+$0.13 today

Market cap
$918.30M
Beta
1.04
P/E (TTM)
-5.4
EPS (TTM)
-$3.61
52W Low $5.95High $62.75

Volume 1.32M

Average 0.99M

MLTX Long-term Investments

Investments the company intends to hold for more than a year.

MoonLake ImmunotherapeuticsNASDAQ: MLTX

Long-term Investments · Q1 FY2026 · quarter ended Mar 2026

Long-term investments remains negative

Q1 FY2026 long-term investments was $0, compared with $0 a year earlier.

Context

  • Long-term investments amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Long-term investments increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Long-term Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Long-term Investments history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Long-term Investments vs competitors

How MLTX compares with its peers on the latest reported figures

  • MLTX's Mar 2026 long-term investments of $0 is the 6th highest of the 11 companies compared; the peer median is $202K.
  • Long-term investments amounts to 0.0% of total assets for MLTX, versus a peer median of 0.2%.
MLTX Competitors Peer median
Long-term Investments for MLTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
DNTHDianthus Therapeutics, Inc.Jun 2026$303.63M +487.2%—25.0%
ORKAOruka Therapeutics, Inc.Sep 2026$286.31M +88.7%—23.3%
ACRSAclaris Therapeutics, Inc.Mar 2026$85.37M +0.2%+70.4%43.0%
NRIXNurix Therapeutics, Inc.Aug 2026$14.83M ——1.2%
ATTOAttovia Therapeutics, Inc.Jun 2026$404K ——0.3%
MLTXMoonLake ImmunotherapeuticsMar 2026$0 ——0.0%
ANABAnaptysBio, Inc.Mar 2026$0 -100.0%—0.0%
ALMSAlumis Inc. Common StockJun 2026$0 ——0.0%
ZURAZura Bio LimitedMar 2026$0 ——0.0%
EQEquillium, Inc.Mar 2026$0 ——0.0%
CNTBConnect Biopharma Holdings LimitedDec 2025$0 ——0.0%
Peer median (excluding MLTX) $202K+44.4%+70.4%0.2%

Competitors are the stored peer set for MLTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents8.04M39.51M451.17M180.43M334.52M
Short-term Investments032.61M59.84M267.6M59.45M
Net Receivables148.77K217.13K1.06M2.84M4.87M
Inventory00000
Other Current Assets00000
Total Current Assets9.64M76.51M514.17M474.29M421.69M
Property, Plant & Equipment (Net)45.74K331.97K3.95M3.64M2.14M
Goodwill00000
Intangible Assets00000
Long-term Investments115.04M0000
Tax Assets00000
Other Non-current Assets(115.04M)(0)8.42M0596K
Total Non-current Assets45.74K331.97K12.37M3.64M2.74M
Total Assets9.68M76.84M526.54M477.93M424.43M
Account Payables1.23M47.48K1.46M8.68M0
Short-term Debt15M0001.23M
Tax Payables63.92K109.83K367.98K642.11K0
Deferred Revenue00000
Other Current Liabilities1.3M109.83K2.78M4.24M40.83M
Total Current Liabilities21.09M7.67M9.97M22.46M45.48M
Long-term Debt000074.47M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities239.86K282.21K583.43K620.68K(374K)
Total Non-current Liabilities239.86K411.16K3.08M2.08M74.47M
Total Liabilities21.33M8.08M13.05M24.54M119.95M
Common Stock38.54K5.27K6.3K6.39K7K
Retained Earnings(53.64M)(80.65M)(116.66M)(235.59M)(462.91M)
Accumulated OCI(168.18K)350.95K2.36M5M604K
Other Stockholders Equity00000
Minority Interest019.87M17.82M6.57M0
Total Equity(11.65M)68.77M513.49M453.39M304.48M
Total Debt15M282.58K3.7M2.83M75.71M
Net Debt6.96M(39.22M)(447.47M)(177.6M)(258.81M)

MoonLake Immunotherapeutics

NASDAQ:MLTX

Intrinsic Alpha fair value

Locked

Current Price

$10.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.